Moreover, the distinctive genotype with activating HER2 mutation, CDKN2A deletion and truncating ATRX mutation, which are identical to those reported in the cited abstract [14], all argue for a distinctive entity unrelated to melanoma, MPNST, or any of the established sarcoma types of the female genital tract or the soft tissues. Here, CDKN2A is linked to malignant peripheral nerve sheath tumor.